Overview

The Colitis Once Daily Asacol Study

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the safety and effectiveness of dosing mesalazine 800 mg tablets (Asacol®) at 2.4 g once daily versus divided doses three times daily in the maintenance of remission of ulcerative colitis.

Phase:

Phase 3

Details

Lead Sponsor:

Cardiff and Vale University Health Board

Collaborator:

Procter and Gamble

Treatments:

Mesalamine